- Home
- GAN vs MGX Comparison
GAN vs MGX Comparison
Compare GAN & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAN
- MGX
- Stock Information
- Founded
- GAN 1999
- MGX 2018
- Country
- GAN United States
- MGX United States
- Employees
- GAN N/A
- MGX N/A
- Industry
- GAN Computer Software: Programming Data Processing
- MGX
- Sector
- GAN Technology
- MGX
- Exchange
- GAN Nasdaq
- MGX NYSE
- Market Cap
- GAN 81.1M
- MGX 65.0M
- IPO Year
- GAN 2020
- MGX 2024
- Fundamental
- Price
- GAN $1.82
- MGX $1.51
- Analyst Decision
- GAN
- MGX Strong Buy
- Analyst Count
- GAN 0
- MGX 4
- Target Price
- GAN N/A
- MGX $14.75
- AVG Volume (30 Days)
- GAN 96.1K
- MGX 355.5K
- Earning Date
- GAN 05-09-2025
- MGX 05-16-2025
- Dividend Yield
- GAN N/A
- MGX N/A
- EPS Growth
- GAN N/A
- MGX N/A
- EPS
- GAN N/A
- MGX N/A
- Revenue
- GAN $133,713,000.00
- MGX $52,295,000.00
- Revenue This Year
- GAN $12.60
- MGX N/A
- Revenue Next Year
- GAN $5.02
- MGX $6.95
- P/E Ratio
- GAN N/A
- MGX N/A
- Revenue Growth
- GAN 7.02
- MGX 16.84
- 52 Week Low
- GAN $1.23
- MGX $1.23
- 52 Week High
- GAN $1.90
- MGX $8.18
- Technical
- Relative Strength Index (RSI)
- GAN 62.72
- MGX 45.48
- Support Level
- GAN $1.73
- MGX $1.40
- Resistance Level
- GAN $1.82
- MGX $1.64
- Average True Range (ATR)
- GAN 0.04
- MGX 0.14
- MACD
- GAN 0.01
- MGX -0.00
- Stochastic Oscillator
- GAN 83.33
- MGX 26.19
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.